Wall Street analyst estimates
Wall Street analysts estimate that Novartis will report revenues of $13.4 billion during the fourth quarter of 2018, a 4.0% increase in year-over-year revenues as compared to $12.9 billion during the fourth quarter of 2017. The earnings-per-share is estimated at $1.29 during the fourth quarter of 2018. Analysts estimate the net income margin to increase to 22.1% during the fourth quarter of 2018 as compared to 21.8% during the fourth quarter of 2017.
The above chart compares changes in analysts’ recommendations for Novartis since January 2018.
Novartis’s stock price has increased by nearly 1.2% during the last 12 months and increased by ~3.8% in 2018 year-to-date. Further, analysts estimate the stock has a potential to return ~13.0% over the next 12 months. Wall Street analysts have a 12-month target price of $98.50 per share as compared to the last price of $87.19 per share as of October 19.
Two analysts are tracking Novartis ADR. Both these analysts are bullish on Novartis and recommend a “strong buy.” The consensus rating for Novartis ADR is 1.0, representing a “strong buy” for momentum investors.
Also, as of October 22, 27 analysts are covering Novartis stock listed on the Six Swiss Exchange. Of these, seven analysts recommend a “strong buy,” seven analysts recommend a “buy,” and 13 analysts recommend a “hold.” None of the analysts recommend a “sell.” The consensus rating for Novartis stands at 2.22, which represents a buy for long-term growth investors and value investors.
The Invesco BLDRS Europe Select ADR ETF (ADRU) holds 6.7% of its total investments in Novartis ADR (NVS), 3.1% in Sanofi ADR (SNY), 3.0% in GlaxoSmithKline ADR (GSK), and 2.4% in Novo Nordisk ADR (NVO).